Amphastar Pharmaceuticals, Inc. Other Comprehensive Income (Loss), Net of Tax
Amphastar Pharmaceuticals, Inc. (AMPH) reported Other Comprehensive Income (Loss), Net of Tax of -$1.07 million for the 6-month period ending 2018-06-30, per its 10-Q filed 2018-08-09.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2018-08-09
- Amphastar Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for the quarter ending 2018-06-30 was -$2.26M, a 323.37% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for the quarter ending 2018-03-31 was $1.19M, a 155.36% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for the quarter ending 2017-09-30 was $625.00K, a 473.39% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for the quarter ending 2017-06-30 was $1.01M.
- Amphastar Pharmaceuticals, Inc. other comprehensive income (loss), net of tax for fiscal 2014 was -$1.65M.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2018-06-30 | -$2.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$1.07M 10-Q · filed 2018-08-09 | ||
| 2018-03-31 | $1.19M 10-Q · filed 2018-05-10 | |||
| 2017-09-30 | $625.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $1.64M derived: sum of 2 quarters · filed 2017-11-09 | $2.10M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $1.48M 10-Q · filed 2017-08-09 | ||
| 2017-03-31 | $466.00K 10-Q · filed 2017-05-10 | |||
| 2016-09-30 | $109.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$542.00K derived: sum of 2 quarters · filed 2016-11-09 | -$106.00K 10-Q · filed 2016-11-09 | |
| 2016-06-30 | -$651.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$215.00K 10-Q · filed 2016-08-09 | ||
| 2016-03-31 | $436.00K 10-Q · filed 2016-05-10 | |||
| 2015-09-30 | $374.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $887.00K derived: sum of 2 quarters · filed 2015-11-13 | -$2.11M 10-Q · filed 2015-11-13 | -$1.96M derived: sum of 4 quarters · filed 2015-11-13 |
| 2015-06-30 | $513.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | -$2.48M 10-Q · filed 2015-08-13 | -$2.33M derived: sum of 3 quarters · filed 2015-08-13 | -$3.87M derived: sum of 4 quarters · filed 2015-08-13 |
| 2015-03-31 | -$2.99M 10-Q · filed 2015-05-14 | -$2.84M derived: sum of 2 quarters · filed 2015-05-14 | -$4.38M derived: sum of 3 quarters · filed 2015-05-14 | |
| 2014-12-31 | $149.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-26 | -$1.39M derived: sum of 2 quarters · filed 2015-03-26 | -$1.65M 10-K · filed 2015-03-26 | |
| 2014-09-30 | -$1.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | -$1.80M 10-Q · filed 2014-11-13 | ||
| 2014-06-30 | -$268.00K 10-Q · filed 2014-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |